Key Milestones

2015
2015
The targeted concentration effect and reversibility of
plaque formation were discovered through early lab studies.
2016
2016
Beijing Inno Medicine Co. Ltd. was incorporated.
An in-house R&D team was established and awarded
funds by NSFC and Beijing Science and Technology Commission.
2019
2019
A pilot plant was set up.
Technology transfer from Anzhen Hospital was completed.
Round Pre-A fundraising done with Beijing Science and Technology Investment Group.
2020
2020
Inno Med was moved to Haidian R&D Center.
2021
2021
Formulation YN001 was finalized and scaled up at the pilot plant.
RMB 200 million was raised in Round A.
2022
2022
YN001 secured IND approval from US FDA
Phase I clinical trial was started in Australia
Construction of Shanghai manufacturing site commenced
2023
2023
Phase Ia of YN001 clinical study finished
The Shanghai site was completed and put into operation
YN001 obtained clinical trial approval from NMPA